Value of non-clinical cardiac repolarization assays in supporting the discovery and development of safer medicines.

Value of non-clinical cardiac repolarization assays in supporting the discovery and development of safer medicines.

Item
http://www.wikidata.org/entity/Q37689204
Risk of QT prolongation and torsade de pointes associated with exposure to hydroxyzine: re-evaluation of an established drug.How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines?Reducing QT liability and proarrhythmic risk in drug discovery and development.On the relationship between block of the cardiac Na⁺ channel and drug-induced prolongation of the QRS complex.Allosteric effects of erythromycin pretreatment on thioridazine block of hERG potassium channels.hERG subunit composition determines differential drug sensitivity.Phenotypic profiling of structural cardiotoxins in vitro reveals dependency on multiple mechanisms of toxicity.On-chip constructive cell-network study (II): on-chip quasi-in vivo cardiac toxicity assay for ventricular tachycardia/fibrillation measurement using ring-shaped closed circuit microelectrode with lined-up cardiomyocyte cell networkAn infrared optical pacing system for screening cardiac electrophysiology in human cardiomyocytes.An in silico canine cardiac midmyocardial action potential duration model as a tool for early drug safety assessment.Can non-clinical repolarization assays predict the results of clinical thorough QT studies? Results from a research consortium.
P2860

Value of non-clinical cardiac repolarization assays in supporting the discovery and development of safer medicines.

Item
http://www.wikidata.org/entity/Q37689204
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Value of non-clinical cardiac ...... evelopment of safer medicines.
@en
Value of non-clinical cardiac ...... evelopment of safer medicines.
@nl
type
label
Value of non-clinical cardiac ...... evelopment of safer medicines.
@en
Value of non-clinical cardiac ...... evelopment of safer medicines.
@nl
prefLabel
Value of non-clinical cardiac ...... evelopment of safer medicines.
@en
Value of non-clinical cardiac ...... evelopment of safer medicines.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P5875
P698
P932
P356
P1433
P1476
Value of non-clinical cardiac ...... evelopment of safer medicines.
@en
P2093
P2860
P304
P31
P356
10.1111/J.1476-5381.2009.00530.X
P407
P433
P478
P577
P5875
P698
P932